πŸ“° Key Highlights

OpenAI researcher Miles Wang is set to leave the company to found a startup focused on AI models for drug development, according to four people familiar with the matter, with several other OpenAI researchers expected to join. Sources say the company is in talks to raise about $200 million at a $2 billion valuation. Lightspeed is reportedly discussing leading this round, but the talks are still in progress and details may change. Wang himself disagreed with the funding figures and company description in the report, but did not specify what the correct numbers or details are. This wave of funding activity reflects investors’ deep interest in AI applications driving breakthroughs in life sciences: two-year-old startup Chai Discovery announced on Tuesday that it raised $400 million at a $3.8 billion valuation (co-founder Josh Meier also comes from an OpenAI researcher background); meanwhile, Isomorphic Labs β€” spun off from Google DeepMind β€” also closed a $2.1 billion Series B round in May this year, also focused on AI models for drug development. According to reports, Wang’s new company may focus on developing AI models that can find new indications for existing drugs (including drugs that failed in clinical trials). Since these FDA-approved drugs have already completed safety testing, finding new uses can generate revenue faster than developing new drugs from scratch. Wang joined OpenAI in 2024 after dropping out of Harvard’s Computer Science department, during which time he co-authored multiple research papers exploring how AI can automate and accelerate scientific discovery.

πŸ’¬ JudyAI Lab Perspective

OpenAI researcher Miles Wang is leaving to found an AI drug discovery startup, reportedly in talks to raise $200M at a $2B valuation, with several OpenAI colleagues expected to join. This is yet another example of AI continuing to push into the life sciences space.

This wave of funding activity isn’t a one-off. In the same period, Chai Discovery raised $400M at a $3.8B valuation, and Isomorphic Labs β€” spun off from Google DeepMind β€” closed a $2.1B Series B in May this year, showing investors see AI applied to drug discovery as the next high-value battlefield. Even more noteworthy is that Wang’s new company is reportedly focused on finding new indications for existing drugs that have already passed FDA approval β€” or even failed in clinical trials β€” rather than developing new drugs from scratch. Safety testing is already done, so revenue can come faster. This “old drug, new use” approach reflects a pragmatic AI application logic: instead of tackling the hardest problems, why not use AI to uncover overlooked value on a validated foundation first?

For AI builders, it’s worth asking yourself: do you also have a validated but undervalued asset that AI could rediscover for new uses, instead of always thinking about starting from scratch?

πŸ“… Source Information

πŸ”— Further Reading